Join Free For Buyer|Sign In
CPhI&P-MEC
Professional Online Trade Platform for API, Preparation and Pharmaceutical Machinery and Equipment_EN-CPhI.cn
You are here:  Home >>  

News

Editors' Picks
  • Crushing Defeats—Top Ten R&D Pipelines that Failed in the Second Half of 2017
    Although the Phase I through Phase III failure rate is 90-95%, the odds of success may still be improved in the next generation of drugs launched.
  • A Review of the Class 1 Oncology Drugs Approved in China in Recent Years
    Getting Rid of the Previous Embarrassment of No New Drug in 10 Years

Top Stories

Raising the Dose and Raising the Cost: The Case of Pembrolizumab in Lung Cancer

Raising the Dose and Raising the Cost: The Case of Pembrolizumab in Lung Cancer

After adjusting for inflation, the price per life-year gained of cancer drugs rose from $54 100 to $207 000 over the 20-year time period between ...
By:academic.oup.com
2017.07.24

Market News

Sanofi Pasteur posts 8.3% growth despite 2017 vaccine setbacks
Sanofi Pasteur posts 8.3% growth despite 2017 vaccine setbacks
Despite lots of challenges that cropped up during 2017, Sanofi's vaccines outfit grew revenues 8.3% in the year to €5.1 billion ($6.25 billion), h...
By:fiercepharma
2018.02.12
Follow Us
CPhI Online Trade Platform: Worldwide|English|中国站
Customer Service:  86-400 610 1188 (9: 00-18: 00, Mon-Fri)
About Us| Contact Us| Terms of Services| Privacy Policy| Intellectual Property Statement| Links | Site Map
Copyright 2006-20 Shanghai UBM Sinoexpo International Exhibition Co Ltd (All Rights Reserved). ICP 05034851-53